2022 Pharmacology Safety 
Pharmaceutical Representative Training
JANUARY 8, 2025
Pharmacology is one of the most fundamental aspects of medication therapy. Without this information, providers cant ensure the safety or efficacy of the medications they prescribe. 1] How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs?
European Pharmaceutical Review
MARCH 9, 2023
1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 13, 2023
While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.
pharmaphorum
JANUARY 17, 2023
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.
European Pharmaceutical Review
DECEMBER 11, 2023
mAbs have well-established safety profiles, high specificity and affinity and long half-lives – they have been used in drug development for more than 30 years. Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities.
European Pharmaceutical Review
JULY 4, 2024
The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.
Pharmaceutical Technology
FEBRUARY 8, 2023
In 2022, 54% of FDA new drug approvals were for rare diseases , a significant increase in proportion of approvals in the recent years. Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks.
Expert insights. Personalized for you.
52 
Let's personalize your content